NCT02927912 is a Phase 2 clinical trial of Electron Beam Therapy in Stage IA Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.

Who is sponsoring NCT02927912?

NCT02927912 is sponsored by Ohio State University Comprehensive Cancer Center.

What drugs are being tested in NCT02927912?

Interventions in NCT02927912: Electron Beam Therapy, Lumpectomy, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Reconstructive Surgery.

What condition does NCT02927912 study?

NCT02927912 studies Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer.

Is NCT02927912 still recruiting?

NCT02927912 is currently active, enrolled. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT02927912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Active, enrolled Phase 2 Last updated 17 February 2026

What this trial tests

Phase 2 trial testing Electron Beam Therapy in Stage IA Breast Cancer in 108 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 October 2017

Primary endpoint
8 May 2025

30 November 2026

Quick facts

Lead sponsor	Ohio State University Comprehensive Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	108
Start date	16 October 2017
Primary completion	8 May 2025
Estimated completion	30 November 2026
Sites	5 locations across Canada, United States

Drugs / interventions tested

Electron Beam Therapy
Lumpectomy
Quality-of-Life Assessment
Questionnaire Administration
Radiation Therapy — full drug profile →
Reconstructive Surgery

Conditions studied

Stage IA Breast Cancer — all drugs for Stage IA Breast Cancer →
Stage IB Breast Cancer — all drugs for Stage IB Breast Cancer →
Stage IIA Breast Cancer — all drugs for Stage IIA Breast Cancer →
Stage IIB Breast Cancer — all drugs for Stage IIB Breast Cancer →

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, female only, with Stage IA Breast Cancer or Stage IB Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy.
Arenas M, Bölükbaşı Y, Boersma LJ, Offersen B, et al · · 2025 · cited 2× · PMID 39854807 · DOI 10.1016/j.breast.2025.103881

Verify or expand the search:

Other trials of Electron Beam Therapy

Trials testing the same drug.

NCT05515692 — Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease · EARLY_PHASE1 · withdrawn

Other recruiting trials for Stage IA Breast Cancer

Currently open trials in the same condition.

NCT05318274 — Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. · NA · active not recruiting
NCT01570998 — Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery · NA · active not recruiting

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02927912 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02927912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing